Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
Commentary|Articles|September 17, 2025
Letters From White House Could Encourage Some Compliance With Most-Favored-Nation Executive Order, Broad Agreements Unlikely: Q&A With Kathy Oubre, MS
Author(s)Julia Bonavitacola, Kathy Oubre, MS
New demands to follow the most favored nation executive order could lead to some compliance but it is unknown just how effective they will be across all health care.
In the second part of her Q&A, Kathy Oubre, MS, discusses the recent updates surrounding the most favored nation (MFN) executive order, including how the discussion of tariffs might play into drug pricing and the recent letters that President Donald Trump sent to pharmaceutical companies in July to demand more swift action on the executive order.
Related to this article
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.
All 50 states have applied for CMS's GENEROUS Model, a Medicaid drug pricing program expected to save $64.3 billion over the next decade.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.